Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
More News related to COV
- Nuvo Research announces organizational changes
- Covidien Completes Sale of Oxygen Therapy Product Line
- Chart's CAIRE Completes Acquisition of Covidien's Oxygen Therapy Business
- Covidien to Present at Piper Jaffray Health Care Conference
- Covidien (COV) Announces FDA Extends Review of NDA for Exalgo
More News related to Corporate News
- Financial Group Moving Higher Amid BofA TARP Repayment News (BAC, C, WFC, XLF, FAS)
- Lexington Realty Trust (LXP) Sells Office Facility in Columbia, SC
- BofA (BAC) Confirms That It Will Repay $45B in TARP Funds
- EQT Corp.'s (EQT) Board Approves Capital Budget for 2010
- Morgan Stanley (MS) may restructure its real estate fund -WSJ
Covidien (NYSE: COV) announced that Health Canada has approved the Company's Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien's generic product is fully substitutable for Cardiolite(R), a myocardial perfusion imaging agent used for detecting coronary artery disease.
With Health Canada approval of the ANDS, which was filed by the Company's Canadian subsidiary, Covidien's generic product is expected to be available for customers in Canada this summer. The Company's generic product also is available in the U.S., the U.K., Denmark, Germany and Puerto Rico.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
